Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Sun Pharmaceutical Industries Ltd drops for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
Sun Pharma shares slip post Q4; analysts cautious on near-term upside
In the March quarter, Sun Pharma reported net profit at ₹2,714 crore, as compared to ₹2,150 crore a year ago, up 26.2 per cent year-on-year (Y-o-Y)
Sun Pharma Q4 PAT jumps 26% YoY to Rs 2,714 cr
Sun Pharmaceutical Industries has reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago.
Retail health premium growth rises to 31% YoY in April 2026, anchoring non-life insurance sector: Kotak Institutional Securities
Indian non-life insurance saw robust growth in April 2026. Retail health premiums surged 31 percent year-on-year. Motor insurance also performed well. Private players and standalone health insurers are gaining market share from public sector companies. Commercial lines faced challenges, though marine and engineering segments showed resilience. This indicates a dynamic shift in the insurance landscape.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Aditya Birla Group stocks: Grasim hits new peak; Voda Idea up 46% in 1-mth
Grasim is the flagship company of Aditya Birla Group, which is led by Kumar Mangalam Birla; while, the group holds substantial stake in Vodafone Idea.
Stocks to Watch for May 22: LIC, ITC, Max Health, Nykaa, Tata Steel and more
From ITC reporting a 5% year-on-year increase in consolidated net profit to Sun TV Network reporting a subdued set of fourth-quarter earnings, here are some stocks to track ahead of Friday's trading session.
Stocks to Watch for May 21: Aditya Birla Capital, Dr Reddy's Lab, Jubilant Food, Bosch India and more
From Dr Reddy's Laboratories announcing the launch of its oral semaglutide biosimilar in India under the brand name Obeda to Whirlpool of India Ltd reporting a 32.7% year-on-year decline in net profit Q4, here are some stocks to track ahead of Thursday trading session.
Zydus Lifesciences Shares Rally After Q4 Result, Share Buyback Announcement
The sharp rally comes on the back of Zydus Life's Q4FY26 earnings, where the company reported a consolidated net profit of Rs 1,272.5 crore for the March quarter, up 8.7% year-on-year.
Selling at higher levels turns 23,800 into key barrier for Nifty: Analysts
Benchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest buying on dips and selling on rallies within the 23,800-23,200 range. Specific stock recommendations include Indus Towers, Samvardhana Motherson International, Aditya Birla Capital, Sun Pharmaceutical Industries, and Arvind Limited. Investors are advised to consider these opportunities.
Aditya Birla Group to invest $500 million in Vodafone Idea as revival signal strengthens
Aditya Birla Group is injecting ₹4,730 crore into Vodafone Idea (Vi) through a preferential allotment, bolstering the telecom operator's financial standing. This capital infusion follows Kumar Mangalam Birla's return as chairman and aims to support Vi's efforts to compete with rivals Reliance Jio and Bharti Airtel.